On October 2, GENFLEET-B fell 5.09% in regular trading, trading at HK$31.32/share, with turnover of HK$6.717 million. The stock had surged 11.56% on October 1 alone, building significant short-term cumulative gains that triggered profit-taking pressure.

On the news front, Ourea Biotech HK Limited sold 6 million shares on September 24 at HK$27.30 per share, totaling approximately HK$164 million. The disposal reduced its stake from 6.34% to 4.64%, creating overhang pressure. Ourea Biotech is controlled by HL Partners II L.P., a Cayman Islands-incorporated limited partnership managed by HL GP II Company Limited.

The decline also coincided with broad weakness across the biotechnology sector. Among sector peers, INNOVENT BIO fell 4.23%, BEONE MEDICINES dropped 6.74%, AKESO declined 3.04%, 3SBIO lost 5.37%, and SKB BIO slipped 4.15%.

Notably, the company had recently benefited from its oral KRAS G12D inhibitor GFH375 being proposed for breakthrough therapy designation by CDE for colorectal cancer, and had conducted 10 share buybacks totaling approximately HK$25.58 million year-to-date. The company is scheduled to release preliminary GFH375 combination therapy data on October 15.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)